GlobeNewswire

Kinguin Reinvents the Online Gaming Marketplace with ICO Launch of "Krown Tokens"

Dela

TALLINN, Estonia, March 29, 2018 (GLOBE NEWSWIRE) -- Kinguin, one of the world's largest online retailers in the video and PC game industry, announces the launch of its next generation online marketplace - poised to transform this industry. Kinguin has created a truly decentralized e-commerce environment with the launch of "Krown Tokens" - the first-ever digital utility token designed specifically for the online gaming community. "Krowns" will be exclusively traded on the Ethereum blockchain network. Of particular note, Kinguin was also awarded "Best ICO Project, 2018" at the Cryptocurrency World Expo in Berlin, Germany recently.

By tokenizing their marketplace, a new generation of online players around the world can now monetize their game experience, enabling an entire global gaming community to profit from the structure and adoption of this decentralized economy. This is a trusted peer-to-peer network to buy, sell, and trade digital games, in-game items, and other game-related services. Gamers can monetize such services as coaching, in-game training and other freelance services to fellow players - all with increased transparency and security.

"When we started Kinguin, we wanted to support and empower a rapidly growing community, that we believed was underserved," notes Viktor Wanli, CEO and founder of Kinguin. "We are gamers ourselves and wanted our community to be able to freely trade their digital property, and now we are evolving our platform to the next generation with blockchain and smart contracts. Our users will continue to enjoy buying, selling, trading digital games, items, and now services, but with even more confidence that they're operating on a trusted and secure network."

In 2013, Kinguin, pioneered the first online marketplace to sell secondary cd-keys, digital games and goods. It has since saved its community of 7 million gamers more than 175 MM USD globally.  The company realized early on that the video game industry had transitioned into a community experience, and to better meet the needs of this community, has taken its marketplace to the next level.

Kinguin believes in fundamental player rights of the gamer community, and the concept of decentralization provides a platform where free trade of digital products will ensure players aren't subject to unfair exploitation.

"Today's free-to-play game market is experiencing record-shattering growth, primarily by relying on players to invest a significant amount of time and money," says Kim Rom, Chief Gaming Officer for Kinguin, and a 20-year veteran of gaming and esports. "However, there hasn't been much focus on value creation for the player, and there's a new generation of gamers and creators failing to monetize their biggest passion - until now. We can give control and earning power back to our community, by opening up revenue streams with our decentralized marketplace."

With this launch, Kinguin has created an entirely new category - a "micro-services industry" for the global gaming community. It also plans to rollout a series of new features and developments within the next 6 months.

Krown Tokens
Kinguin seeks to raise 50MM USD through a series of private and public rounds over the next 2 years. Each round will be tied to new product launches, so potential backers can be a part of the development, testing and verification process, and track progress. The reason for this approach is that unlike other ICO offerings Kinguin elects to receive payments over a structured period of time, as it moves forward from one milestone to the next. This method is most effective, to incrementally distribute funds back where they will be best utilized as the project develops.

The Krown pre-sale began March 15, 2018 at 3:03 PM CET, and the main sale will begin April 12, 2018 at 24:00 CET.  Krowns will not be available for purchase from residents in, or citizens of the USA, and China.

Krowns do not represent company shares or give rights to revenue sharing. The Krown is exclusively a utility token for accessing digital gaming experiences and items on the Kinguin platform, and from participating partner sites.

Kinguin will enforce stricter-than-market-standard criteria in the approval process, and all rounds will adhere to strict KYC (Know Your Customer) and AML (Anti-Money Laundering) policies. The company has also engaged MC2 Solutions to develop its smart contracts, all of which will undergo independent third-party security and code audits, to ensure security and integrity. They will also be available on GitHub for review by the community and all interested parties.

Kinguin.io is a legally registered entity in Estonia and compliant with European laws and regulations. Interested participants can transfer most crypto or fiat currencies and will receive digital ERC23 compliant Krown Tokens in return.

Kinguin is happy to work with its users to educate them about the Krown, but is not a financial advisor. The company strongly recommends that participants consult with their own advisors.

For more information and complete details about Krowns, visit: 
https://kinguin.io/ and Telegram channel: https://t.me/KinguinICOPublic.

About Kinguin

Since 2013, Kinguin has become the largest alternative marketplace to Steam, Origin, and Battle.net with more than 7 million loyal customers, globally. Its mission is to provide users the opportunity to buy, sell and trade video games at a fair price with an innovative hassle-free, trusted and secure platform.

Community is at the heart of Kinguin, and it supports Kinguin Guinness World Record and Kinguin For Charity Tournaments together with Child's Play Foundation.

For more information visit, https://www.kinguin.net and https://www.kinguin.io.

Media Contact
Cameron Carson, Kinguin
cameron.carson@kinguin.io




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Kinguin Limited via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum